Document:

f8k103111ex10iv_bioneutral.htm

Exhibit 10.4

 

	
PREFERRED STOCK DRAWDOWN AGREEMENT

 

THIS PREFERRED STOCK DRAWDOWN AGREEMENT (this “Agreement”) is made as of November 7, 2011 by and between BioNeutral Group, Inc., a Nevada corporation (the “Company”), and Vinfluence Pty Ltd ACN 147 137 899 (“Purchaser”).

 

RECITALS

 

WHEREAS, the Company desires to sell to Purchaser and Purchaser desires to purchase from the Company the number of shares of the Company’s Series E Convertible Preferred Stock (“Preferred Stock”) set forth herein at a price of $10.00 per share, subject to the terms and conditions of this Agreement and the other documents or instruments contemplated hereby.

 

 NOW, THEREFORE, the parties hereto hereby agree as follows:

 

AGREEMENT

 

Section 1.             Sale and Issuance of Preferred Stock.

 

(a) Subject to the terms and conditions of this Agreement, the Company has authorized the sale and issuance (the "Issuance") to Purchaser of an aggregate of up to 140,000 shares of the Preferred Stock at $10.00 per share for an aggregate commitment amount of up to $1,400,000 (the “Aggregate Commitment”) which the Purchaser has agreed to provide to the Company on a monthly basis commencing on April 1, 2012 and ending on October 1, 2012 (the “Commitment Period”) in order to purchase Preferred Stock pursuant to the terms and conditions of this Agreement. The Purchaser shall purchase an aggregate of up to 140,000 shares of Preferred Stock in monthly increments of up to $200,000 (the “Maximum Advance Amount”), upon receipt of a Drawdown Notice from the Company.  Drawdown Notice shall mean a written notice in the form of Exhibit A attached hereto to the Purchaser setting forth the amount of the advance.

 

(b) The rights and preferences of the Preferred Stock shall be set forth in a Certificate of Designations and Preferences to be filed with the Secretary of State of the State of Nevada in form and substance as set forth on Exhibit B hereto.

 

Section 2.              Mechanics/Closings.

 

2.1          Drawdown Notice. On a monthly basis during the Commitment Period, the Company may request the Purchaser to purchase shares of Preferred Stock by delivering a Drawdown Notice to the Investor, subject to the conditions set forth herein; provided, however, the amount for each Advance as designated by the Company in the applicable Drawdown Notice shall not be more than the Maximum Advance Amount and the aggregate amount of the Advances pursuant to this Agreement shall not exceed the Aggregate Commitment.  The Company shall have discretion as to whether it issues a Drawdown Notice to sell shares of Preferred Stock, and, except for conditions outside the Purchaser’s control, the Purchaser shall be obligated to purchase from the Company, shares of the Preferred Stock as requested in the Drawdown Notice.

 

  

1

  

 

2.2          Date of Delivery of Drawdown Notice. A Drawdown Notice shall be deemed delivered on: (i) the Trading Day it is received by email to Wayne@Noblemenventures.com if such notice is received prior to 5:00 pm Eastern Time; or (ii) the immediately succeeding Trading Day if a Drawdown Notice is received by facsimile or otherwise after 5:00 pm Eastern Time on a Trading Day or at any time on a day which is not a Trading Day.  No Drawdown Notice may be deemed delivered on a day that is not a Trading Day.

 

2.3         Each Closing shall take place within three (3) business days of the Purchaser’s receipt of a Drawdown Notice issued by the Company, provided the conditions set forth in Section 5.2 below have been satisfied.

 

2.4         At each Closing, the Company shall issue and deliver to Gersten Savage, LLP, as escrow agent (“Escrow Agent”), a stock certificate representing the Preferred Stock, against receipt by Escrow Agent of a wire transfer in an amount equal to the Purchase Price.  Upon receipt of the Purchase Price and the Preferred Stock certificate for each Closing, and in accordance with the Escrow Agreement entered into by each of Purchaser and Company, Escrow Agent shall release the Purchase Price to the Company and the Preferred Stock certificate to the Buyer.

 

Section 3.             Representations and Warranties of the Company.

 

The Company hereby represents and warrants to Purchaser as follows:

 

3.1           Capitalization of the Company. Immediately prior to the date hereof, the authorized capital stock of the Company shall consist of a total of 200,000,000 shares of Common Stock, $0.00001 par value per share (the “Common Stock”) of which 79,389,092 are issued and outstanding, (this number includes the conversion of the 83,762 shares of preferred stock of BioNeutral Laboratories Corporation USA (“Bio USA”)) and 5,000,000 shares of Preferred Stock, $0.001 par value, of which 800,000 are designated as Series A, 213,500 are designated as Series B, 100,000 are designated as Series C, 231,100 are designated as Series D and 140,000 are designated as Series E.  There are 83,762 shares of Series A preferred stock outstanding of BioN USA which can be converted into common stock and no shares of Series B, Series C, Series D or Series E preferred stock outstanding.  Other than as set forth in the Company’s filings with the Securities and Exchange Commission (“Filings”), there are no commitments to issue, and there are no outstanding warrants, options, convertible securities or debt, preferred stock, or any other securities as of the date of Closing, except as set forth herein.  In addition, other than as set forth in the Company’s Filings, there are no conversion or exchange privileges, preemptive rights, or other rights or agreements to purchase or otherwise acquire or issue any securities of the Company, and there is no agreement or understanding between any persons and/or entities, which affects or relates to the voting or giving of written consents with respect to any security of the Company or any instrument or security exercisable or exchangeable for, or convertible into any security of the Company, except that the Company has an obligation to issue certain shares of common stock as set forth in Schedule A hereto.

 

  

2

  

 

3.2          Organization.

 

The Company is duly organized, validly existing and in good standing under the laws of the State of Nevada and is qualified to conduct its business as a foreign corporation in each jurisdiction where the failure to be so qualified would have a material adverse effect on the Company.

 

3.3          Authorization of Agreement, Etc.

 

The execution, delivery and performance by the Company of this Agreement and each other document or instrument contemplated hereby or thereby (collectively, the "Financing Documents") have been duly authorized by all requisite corporate action by the Company; and this Agreement and each other Financing Document have been duly executed and delivered by the Company.  Each of the Financing Documents, when executed and delivered by the Company, constitutes the valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or other similar laws affecting creditors' rights and remedies generally, and subject as to enforceability to general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity).

 

3.4          Subsidiaries.

The Company does not own, directly or indirectly, any capital stock or other equity securities of any other corporation, partnership, limited liability company, association or other business entity other than as set forth in the Filings. The Company is not a participant in any joint venture, partnership or similar arrangement.  The Company owns 89.6% of Bioneutral Laboratories Corporation USA.

3.5          Financial Statements.

The Company’s financial statements (“Financial Statements”) contained in its Filings have been prepared in accordance with U.S. GAAP applied on a consistent basis throughout the periods indicated and with each other, except that the unaudited Financial Statements do not contain all footnotes required by U.S. GAAP.  The Financial Statements fairly present the financial condition and operating results of the Company as of the dates, and for the periods, indicated therein, subject to normal year-end audit adjustments.  Except as set forth in the Financial Statements, the Company has no material liabilities (contingent or otherwise).  Except as disclosed in the Financial Statements, the Company is not a guarantor or indemnitor of any indebtedness of any other person, firm or corporation.  The Company maintains and will continue to maintain a standard system of accounting established and administered in accordance with U.S. GAAP until Closing.

3.6          No Conflicts.

Neither the Company, nor any subsidiary, is in violation of, in conflict with, in breach of or in default under any term or provision of, and no right of any party to accelerate, terminate, modify or cancel has come into existence under, (i) its Certificate of Incorporation or By-laws (each as may have been amended, supplemented or restated), (ii) any provision of any judgment, writ, injunction, decree or order to which the any of them is a party; or (iii) any law, statute, rule or regulation applicable to any of them.

 

  

3

  

 

3.7          Litigation.

There is no action, suit, proceeding or investigation pending or currently threatened against the Company or any subsidiary that may affect the validity of this Agreement or the right of the Company to enter into this Agreement or to consummate the transactions contemplated hereby.  There is no action, suit, proceeding or investigation pending or currently threatened against the Company or its subsidiaries, before any court or by or before any governmental body or any arbitration board or tribunal, nor is there any judgment, decree, injunction or order of any court, governmental department, commission, agency, instrumentality or arbitrator against the Company or any of its subsidiaries other than these described in the Filings.  The Company and its subsidiaries are not a party or subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality.  There is no action, suit, proceeding or investigation by the Company or any subsidiary currently pending or which the Company intends to initiate.

3.8          ‘34 Act Reports.

None of the Company’s Filings contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements therein not misleading, in light of the circumstances in which they were made.  For the period between the filing of the Company’s Form 10-Q for the period ended July 31, 2011 and the date of this Agreement, the Company has made all required filings and disclosures on Form 8-K pursuant to the rules and regulations promulgated thereunder.

Section 4.              Representations and Warranties of Purchaser.

 

Purchaser hereby represents and warrants to the Company that each of the following representations and warranties will be true as of the date hereof:

 

4.1          Authorization of the Documents.

 

Purchaser has all requisite power and authority (corporate or otherwise) to execute, deliver and perform the Financing Documents and the transactions contemplated thereby, and the execution, delivery and performance by Purchaser of the Financing Documents have been duly authorized by all requisite action by Purchaser and each such Financing Document, when executed and delivered by Purchaser, constitutes a valid and binding obligation of Purchaser, enforceable against Purchaser in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or other similar laws affecting creditors' rights and remedies generally, and subject, as to enforceability, to general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity).

 

  

4

  

 

4.2          Investment Representations.

 

All of the representations, warranties and information of Purchaser provided in the Subscription Application dated ___________ are incorporated herein and made a part hereof by this reference and shall be true at the Closing with the same effect as though made at the Closing.

 

4.3          Review of Public Filings.

 

Purchaser has had the ability to review all of the Company’s filings and to ask the Company any questions in connection with its review thereof.

 

Section 5.             Conditions for Advance and Conditions to Closing.

 

5.1          Conditions Precedent to the Obligations of the Company.  The obligation hereunder of the Company to issue and sell the shares of Common Stock to the Purchaser incident to each Closing is subject to the satisfaction, or waiver by the Company, at or before each such Closing, of each of the conditions set forth below.

 

(a) Accuracy of the Purchaser’s Representations and Warranties.  The representations and warranties of the Purchaser shall be true and correct in all material respects.

 

(b) Performance by the Purchaser.  The Purchaser shall have performed, satisfied and complied in all respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with my the Purchaser at or prior to such Closing.

 

5.2          Conditions Precedent to the Right of the Company to Deliver a Drawdown Notice.  The right of the Company to deliver a Drawdown Notice is subject to the fulfillment by the Company, on such Drawdown Notice (a “Condition Satisfaction Date”), of each of the following conditions:

 

(a)  Fundamental Changes.  There shall not exist any material adverse changes to the market or the business of the Company, as determined by the Purchaser in its sole discretion.

 

(b)  Performance by the Company.  The Company shall have performed, satisfied and complied in all materials respects with all covenants, agreements and conditions required by this Agreement to be performed satisfied or complied with by the Company at or prior to each Closing and the Company shall not be in breach or default of any other agreement between Company and Purchaser.

 

(c)   No Injunction.  No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority or competent jurisdiction that prohibits or directly and adversely affects any of the transactions contemplated by this Agreement, and no proceeding shall have been commenced that may have the effect of prohibiting or adversely affecting any of the transactions contemplated by this Agreement.

 

  

5

  

 

(d)  No Suspension of Trading in or Delisting of Common Stock. The trading of the Common Stock is not suspended by the SEC or the Principal Market (if the Common Stock is traded on a Principal Market).  The issuance of shares of Common Stock with respect to the applicable Closing, if any, shall not violate the shareholder approval requirements of the Principal Market (if the Common Stock is traded on a Principal Market).  The Company shall not have received any notice threatening the continued listing or quotation of the Common Stock on the Principal Market (if the Common Stock is traded on a Principal Market).  For purposes hereof a “Principal Market” shall mean any of the following: OTC Bulletin Board, OTC Markets, Nasdaq Stock Market, NYSE Amex, or NYSE.

 

(e)          Maximum Advance Amount. The amount of an Advance requested by the Company shall not exceed the Maximum Advance Amount.

 

(f)           34 Act Filings. The Company shall have timely made all filings (“SEC Filings”) required to be made by it pursuant to applicable securities laws (including without limitation, all filings required under the Securities Exchange Act of 1934, which include Forms 10-Q, 10-K, 8-K, etc.) and none of such SEC Filings shall contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made not misleading.

 

(g)          Executed Drawdown Notice. The Investor shall have received the Drawdown Notice executed by an officer of the Company and the representations contained in such Drawdown Notice shall be true and correct as of each Closing.

 

 Section 6.            Brokers and Finders.

 

The Company shall not be obligated to pay any commission, brokerage fee or finder’s fee based on any alleged agreement or understanding between Purchaser and a third person in respect of the transactions contemplated hereby.  Purchaser hereby agrees to indemnify the Company against any claim by any third person for any commission, brokerage or finder's fee or other payment with respect to this Agreement or the transactions contemplated hereby based on any alleged agreement or understanding between Purchaser and such third person, whether express or implied from the actions of Purchaser.

 

Section 7.             Successors and Assigns.

 

This Agreement shall bind and inure to the benefit of the Company, Purchaser and their respective successors and assigns.

 

Section 8.              Entire Agreement.

 

This Agreement and the other writings and agreements referred to in this Agreement or delivered pursuant to this Agreement contain the entire understanding of the parties with respect to the subject matter hereof and supersedes all prior agreements and understandings among the parties with respect thereto.

 

  

6

  

 

Section 9.              Notices.

 

All notices, demands and requests of any kind to be delivered to any party in connection with this Agreement shall be in writing and shall be deemed to have been duly given if personally delivered or if sent by internationally-recognized overnight courier or by registered or certified mail, return receipt requested and postage prepaid, addressed as follows:

 

if to the Company, to:

 

BioNeutral Group, Inc.

211 Warren Street

Newark, New Jersey 07103

Attention:  President

if to Purchaser, to:

 

Vinfluence Pty Ltd ACN 147 137 899

Level 14 No 1 Alfred Street Sydney

Australia

Email: Wayne@noblemenventures.com

or to such other address as the party to whom notice is to be given may have furnished to the other parties to this Agreement in writing in accordance with the provisions of this Section 8.  Any such notice or communication shall be deemed to have been received (i) in the case of personal delivery, on the date of such delivery, (ii) in the case of internationally-recognized overnight courier, on the next business day after the date when sent and (iii) in the case of mailing, on the third business day following that on which the piece of mail containing such communication is posted.

 

Section 10.           Amendments.

 

This Agreement may not be modified or amended, or any of the provisions of this Agreement waived, except by written agreement of the Company and Purchaser.

 

Section 11.           Governing  Law; Waiver of Jury Trial.

 

All questions concerning the construction, interpretation and validity of this Agreement shall be governed by and construed and enforced in accordance with the domestic laws of New York without giving effect to any choice or conflict of law provision or rule (whether in the State of New York or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of New York.  In furtherance of the foregoing, the internal laws of the State of New York will control the interpretation and construction of this Agreement, even if under such jurisdiction's choice of law or conflict of law analysis, the substantive law of some other jurisdiction would ordinarily or necessarily apply.

 

  

7

  

 

BECAUSE DISPUTES ARISING IN CONNECTION WITH COMPLEX FINANCIAL TRANSACTIONS ARE MOST QUICKLY AND ECONOMICALLY RESOLVED BY AN EXPERIENCED AND EXPERT PERSON AND THE PARTIES WISH APPLICABLE LAWS TO APPLY (RATHER THAN ARBITRATION RULES), THE PARTIES DESIRE THAT THEIR DISPUTES BE RESOLVED BY A JUDGE APPLYING SUCH APPLICABLE LAWS.  THEREFORE, TO ACHIEVE THE BEST COMBINATION OF THE BENEFITS OF THE JUDICIAL SYSTEM AND OF ARBITRATION, THE PARTIES HERETO WAIVE ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT OR PROCEEDING BROUGHT TO ENFORCE OR DEFEND ANY RIGHTS OR REMEDIES UNDER THIS AGREEMENT OR ANY DOCUMENTS RELATED HERETO.

 

Section 12.           Assignment; Termination

 

       12.1                 Assignment.  Neither this Agreement nor any rights of the Company hereunder may be assigned to any other Person.

 

       12.2                 Termination.  The obligations of the Purchaser to make Advances under this Agreement shall terminate at the end of the Commitment Period.

 

Section 13.           Submission to Jurisdiction.

 

Any legal action or proceeding with respect to this Agreement may be brought in the courts of Australia, by execution and delivery of this Agreement, the Company hereby accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of the aforesaid courts.  Purchaser hereby irrevocably waives, in connection with any such action or proceeding, any objection, including, without limitation, any objection to the venue or based on the grounds of forum non conveniens, which it may now or hereafter have to the bringing of any such action or proceeding in such respective jurisdictions.  Purchaser hereby irrevocably consents to the service of process of any of the aforementioned courts in any such action or proceeding by the mailing of copies thereof by registered or certified mail, postage prepaid, to it at its address as set forth herein.

 

Section 14.           Severability.

 

It is the desire and intent of the parties that the provisions of this Agreement be enforced to the fullest extent permissible under the law and public policies applied in each jurisdiction in which enforcement is sought.  Accordingly, in the event that any provision of this Agreement would be held in any jurisdiction to be invalid, prohibited or unenforceable for any reason, such provision, as to such jurisdiction, shall be ineffective, without invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any jurisdiction.  Notwithstanding the foregoing, if such provision could be more narrowly drawn so as not to be invalid, prohibited or unenforceable in such jurisdiction, it shall, as to such jurisdiction, be so narrowly drawn, without invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction.

 

Section 15.           Independence of Agreements, Covenants, Representations and Warranties.

 

All agreements and covenants hereunder shall be given independent effect so that if a certain action or condition constitutes a default under a certain agreement or covenant, the fact that such action or condition is permitted by another agreement or covenant shall not affect the occurrence of such default, unless expressly permitted under an exception to such covenant.  In addition, all representations and warranties hereunder shall be given independent effect so that if a particular representation or warranty proves to be incorrect or is breached, the fact that another representation or warranty concerning the same or similar subject matter is correct or is not breached will not affect the incorrectness of or a breach of a representation and warranty hereunder.  The exhibits and any schedules attached hereto are hereby made part of this Agreement in all respects.

 

  

8

  

 

Section 16.           Counterparts.

 

This Agreement may be executed in any number of counterparts, and each such counterpart of this Agreement shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement.  Facsimile and .pdf counterpart signatures to this Agreement shall be acceptable and binding.

 

Section 17.           Headings.

 

The section and paragraph headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.

 

Section 18.           Expenses.

 

Purchaser shall pay Purchaser’s own fees and expenses incurred in connection with the negotiation, review, execution and delivery of the Financing Documents.

 

Section 19.           Preparation of Agreement.

 

Each party to this Agreement acknowledges that:  (i) the party had the advice of, or sufficient opportunity to obtain the advice of, legal counsel separate and independent of legal counsel for any other party hereto; (ii) the terms of the transactions contemplated by this Agreement are fair and reasonable to such party; and (iii) such party has voluntarily entered into the transactions contemplated by this Agreement without duress or coercion.  Each party further acknowledges that such party was not represented by the legal counsel of any other party hereto in connection with the transactions contemplated by this Agreement, nor was he or it under any belief or understanding that such legal counsel was representing his or its interests.  Each party agrees that no conflict, omission or ambiguity in this Agreement, or the interpretation thereof, shall be presumed, implied or otherwise construed against any other party to this Agreement on the basis that such party was responsible for drafting this Agreement.

[SIGNATURE PAGE FOLLOWS]

 

  

9

  

 

IN WITNESS WHEREOF, each of the undersigned has duly executed this Preferred Stock Drawdown Agreement as of the date first written above.

 

COMPANY:

BIONEUTRAL GROUP, INC.

By:  /s/ Andrew Kielbania           

Name: Andrew Kielbania

           Title: Interim Chief Executive Officer

 

 

	
PURCHASER:

 

	
Vinfluence Pty Ltd ACN 147 137 899

 

 

	
/s/ Wayne Johnson                                 

 

Signature of Trustee

 

Address:

 

 

Telephone:

 

Telecopier:

 

  

10

  

 

EXHIBIT A

DRAWDOWN NOTICE

BioNeutral Group, Inc.

 

The undersigned, ______________ hereby certifies with respect to the sale of shares of Preferred Stock of BioNeutral Group, Inc. (the “Company”) issuable in connection with Drawdown Notice, delivered pursuant to the Preferred Stock Drawdown Agreement (the “Agreement”), as follows:

1.  The undersigned is duly elected ___________ of the Company.

2.  There are no fundamental changes to the business of the Company which constitute a fundamental change in the nature of the Company’s business.

3.  The Company has performed in all material respects all covenants and agreements to be performed by the Company and has complied in all material respects with all obligations and conditions contained in the Agreement on or prior to the Drawdown Notice Date.

 

4.  The undersigned hereby represents, warrants and covenants that it has made all filings (“SEC Filings”) required to be made by it pursuant to applicable securities laws (including, without limitation, all filings required under the Securities Exchange Act of 1934, which include Forms 10-Q, 10-K, 8-K, etc.).  All SEC Filings and other public disclosures made by the Company, including without limitation, all press releases, analysts meetings and calls, etc. (collectively, the “Public Disclosures”), have been reviewed and approved for release by the Company’s attorneys and, if containing financial information, the Company’s independent certified public accountants.  None of the Company’s Public Disclosures contain any untrue statement of a material fact of omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.

5.  The Advance requested is ___________________.

The undersigned has executed this Certificate this ________ day of _________.

BioNeutral Group, Inc.

By: ________________________

       Name:

       Title:

 

  

11

  

 

EXHIBIT B

Certificate of Designation

For Nevada Corporations

(Pursuant to NRS 78.1955)

BIONEUTRAL GROUP, INC.

File Number: [___________]

Series E Convertible Preferred Stock, to consist of 140,000 shares of the 5,000,000 Authorized shares of Preferred Stock; and have the following terms:

1. Designation, Amount and Par Value.  The series of preferred stock shall be designated as its Series C Convertible Preferred Stock (the “Preferred Stock”) and the number of shares so designated shall be 140,000 (which shall not be subject to increase without the consent of the holders of a majority of the Preferred Stock (each, a “Holder” and collectively, the “Holders”)).  Each share of Preferred Stock shall have a par value of $.001 per share and a stated value equal to the sum of $10 plus all accrued and unpaid dividends to the date of determination to the extent not previously paid in cash or common stock, par value $.00001 per share (“Common Stock”) of the Company in accordance with the terms hereof (the “Stated Value”).

2. Dividends. Except as provided herein, the holders of outstanding shares of the Preferred Stock shall be entitled to receive cash, stock, or other property, as dividends when, as, and if declared by the Board of Directors of the Company. If shares of the Preferred Stock or the common stock of the Company, par value $0.00001 per share (the "Common Stock") are to be issued as a dividend, any such shares shall be issued at Market Value. "Market Value" for the Common Stock for the purposes of this Certificate of Designation shall mean the average of the bid and ask prices for the Common Stock for the five business days preceding the declaration of a dividend by the Board of Directors. "Market Value" with respect to any shares of the Preferred Stock shall be as determined by the Board of Directors, whose decision shall be final and binding on all parties.

3. Liquidation Rights. Upon the dissolution, liquidation or winding up of the Company, whether voluntary or involuntary, the holders of the then outstanding shares of Preferred Stock shall be entitled to receive out of the assets of the Company for each share of Preferred Stock the Stated Value (the "Liquidation Rate") before any payment or distribution shall be made on the Common Stock, or any other class of capital stock of the Company ranking junior to the Preferred Stock.

(a) The sale, conveyance, exchange or transfer (for cash, shares of stock, securities or other consideration) of all or substantially all the property and assets of the Company shall be deemed a dissolution, liquidation or winding up of the Company for purposes of this Paragraph 3, but the merger, consolidation, or other combination of the Company into or with any other corporation, or the merger, consolidation, or other combination of any other corporation into or with the Company, shall not be deemed a dissolution, liquidation or winding up, voluntary or involuntary, for purposes of this Paragraph 3. As used herein, the "merger, consolidation, or other combination" shall include, without limitation, a forward or reverse triangular merger, or stock exchange of the Company and any of its subsidiaries with any other corporation where the Company is not the surviving entity.

 

  

12

  

 

(b) After the payment to the holders of shares of the Preferred Stock of the full preferential amounts fixed by this Paragraph 3 for shares of the Preferred Stock, the holders of the Preferred Stock as such shall have no right or claim to any of the remaining assets of the Company.

(c) In the event the assets of the Company available for distribution to the holders of the Preferred Stock upon dissolution, liquidation or winding up of the Company shall be insufficient to pay in full all amounts to which such holders are entitled pursuant to this Paragraph 2, no distribution shall be made on account of any shares of a class or series of capital stock of the Company ranking on a parity with the shares of the Preferred Stock, if any, upon such dissolution, liquidation or winding up unless proportionate distributive amounts shall be paid on account of the shares of the Preferred Stock, ratably, in proportion to the full distributive amounts for which holders of all such parity shares are respectively entitled upon such dissolution, liquidation or winding up.

4. Conversion of Preferred Stock. At any time, the holder of shares of the Preferred Stock shall have the right, at such holder's option, to convert any number of shares of the Preferred Stock into shares of the Common Stock. Such right to convert shall commence as of the date the shares of such Preferred Stock are issued to such holder (the "Issue Date") and shall continue thereafter for a period of five years, such period ending on the fifth anniversary of the Issue Date. In the event that the holder of the Preferred Stock elects to convert such shares into Common Stock, the holder shall have 10 days from the date of such notice in which to tender his shares of Preferred Stock to the Company.

Any such conversion shall be upon the other following terms and conditions:

(a) Conversion Rate. Subject to adjustment as provided herein, each one (1) share of the Preferred Stock shall be convertible into fully paid and non-assessable shares of common stock at a conversion price equal to seventy-five percent (75%) of the average closing Bid Price of the Common Stock over the preceding ten (10) days prior to the Drawdown Notice, subject to a floor of $.08 per share (the “Floor Price”) (the "Conversion Rate").  Bid Price shall mean, on any date, the closing bid price (as reported by Bloomberg L.P.) of the Common Stock on the principal trading or market for the Common Stock or if the Common Stock is not traded on a Principal Market, the highest reported bid price for the Common Stock.

(b) Adjustment of Floor Price for Dilution and Other Events. In order to prevent dilution of the rights granted to the holders of shares of the Preferred Stock, the Floor Price will be subject to adjustment from time to time as follows:

(i) Adjustment of Floor Price upon Subdivision or Combination of the Common Stock. If the Company at any time subdivides (by any stock split, stock dividend, recapitalization or otherwise) the authorized Common Stock into a greater number of shares, the Floor Price in effect immediately prior to such subdivision will be proportionately increased. If the Company at any time combines (by combination, reverse stock split or otherwise) the authorized Common Stock into a smaller number of shares, the Floor Price in effect immediately prior to such combination will be proportionately reduced.

  

13

  

 

(ii) Reorganization, Reclassification, Consolidation, Merger or Sale. Any recapitalization, reorganization, reclassification, consolidation, merger, or other similar transaction which is effected in such a way that holders of the Common Stock are entitled to receive (either directly or upon subsequent liquidation) stock, securities or assets with respect to or in exchange for the Common Stock is referred to herein as an "Organic Change." Prior to the consummation of any Organic Change, the Company will make appropriate provision, in form and substance satisfactory to the holders of a majority of the outstanding shares of the Preferred Stock, to ensure that each of the holders of shares of the Preferred Stock will thereafter have the right to acquire and receive in lieu of or in addition to, as the case may be, the shares of the Common Stock immediately theretofore acquirable and receivable upon the conversion of such holder's Preferred Stock, such shares of stock, securities or assets as may be issued or payable with respect to or in exchange for the number of shares of the Common Stock immediately theretofore acquirable and receivable upon the conversion of such holder's shares of the Preferred Stock had such Organic Change not taken place. In any such case, the Company will make appropriate provision, in form and substance satisfactory to the holders of a majority of the outstanding shares of the Preferred Stock, with respect to such holders' rights and interests to ensure that the provisions of this paragraph will thereafter be applicable to the Preferred Stock The Company will not effect any such consolidation or merger, unless prior to the consummation thereof the successor entity resulting from such consolidation or merger, if other than the Company, assumes, by written instrument, in form and substance satisfactory to the holders of a majority of the outstanding shares of the Preferred Stock, the obligation to deliver to each holder of shares of the Preferred Stock such shares of stock, securities or assets as, in accordance with the foregoing provisions, that such holder may be entitled to acquire.

(iii) Notices. Immediately upon any adjustment of the Floor Price, the Company will give written notice of such adjustment to each holder of shares of the Preferred Stock, setting forth in reasonable detail and certifying the calculation of such adjustment. The Company will give written notice to each holder of shares of the Preferred Stock at least 20 days prior to the date on which the Company closes its books or takes a record with respect to any dividend or distribution upon the Common Stock, or with respect to any pro rata subscription offer to holders of the Common Stock. The Company will also give written notice to each holder of shares of the Preferred Stock at least 20 days prior to the date on which any Organic Change, dissolution or liquidation will take place.

(c) Mechanics of Conversion. To convert shares of the Preferred Stock into shares of the Common Stock on any date (the "Conversion Date"), the holder thereof shall (i) deliver or transmit by facsimile to the Company, for receipt on or prior to l1:59 p.m. Eastern Time, on the Conversion Date, a copy of a fully executed notice of conversion in the form attached hereto as Exhibit A (the "Conversion Notice"), and (ii) surrender to a common carrier for delivery to the Company as soon as practicable following such date, the certificates (each a "Preferred Stock Certificate") representing the shares of the Preferred Stock being converted, or an indemnification undertaking with respect to such shares in the case of the loss, theft or destruction thereof, and the originally executed Conversion Notice. Upon receipt by the Company of a facsimile copy of a Conversion Notice, the Company shall immediately send, via facsimile, a confirmation of receipt of such Conversion Notice to such holder. Within three business days of the Company's receipt of the originally executed Conversion Notice and the holder's Preferred Stock Certificate(s), the Company shall issue and surrender to a common carrier for overnight delivery to the address as specified in the Conversion Notice, a certificate, registered in the name of the holder or its designee, for the number of shares of the Common Stock to which the holder is entitled, or at the holder’s option, delivery of the shares of Common Stock via the DWAC system to holder’s brokerage account.

 

  

14

  

 

(d)  Certain Conversion Restrictions.

 

(A) A Holder may not convert shares of Preferred Stock or receive shares of Common Stock as payment of dividends hereunder to the extent such conversion or receipt of such dividend payment would result in the Holder, together with any affiliate thereof, beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (“Exchange Act”) and the rules promulgated thereunder) in excess of 4.999% of the then issued and outstanding shares of Common Stock, including shares issuable upon conversion of, and payment of dividends on, the shares of Preferred Stock held by such Holder after application of this Section.  Since the Holder will not be obligated to report to the Company the number of shares of Common Stock it may hold at the time of a conversion hereunder, unless the conversion at issue would result in the issuance of shares of Common Stock in excess of 4.999% of the then outstanding shares of Common Stock without regard to any other shares which may be beneficially owned by the Holder or an affiliate thereof, the Holder shall have the authority and obligation to determine whether the restriction contained in this Section will limit any particular conversion hereunder and to the extent that the Holder determines that the limitation contained in this Section applies, the determination of which portion of the shares of Preferred Stock are convertible shall be the responsibility and obligation of the Holder.  The provisions of this Section may be waived by a Holder (but only as to itself and not to any other Holder) upon not less than 61 days prior notice to the Company.  Other Holders shall be unaffected by any such waiver.

 

(B) A Holder may not convert shares of Preferred Stock or receive shares of Common Stock as payment of dividends hereunder to the extent such conversion or receipt of such dividend payment would result in the Holder, together with any affiliate thereof, beneficially owning (as determined in accordance with Section 13(d) of the Exchange Act and the rules promulgated thereunder) in excess of 9.999% of the then issued and outstanding shares of Common Stock, including shares issuable upon conversion of, and payment of dividends on, the shares of Preferred Stock held by such Holder after application of this Section.  Since the Holder will not be obligated to report to the Company the number of shares of Common Stock it may hold at the time of a conversion hereunder, unless the conversion at issue would result in the issuance of shares of Common Stock in excess of 9.999% of the then outstanding shares of Common Stock without regard to any other shares which may be beneficially owned by the Holder or an affiliate thereof, the Holder shall have the authority and obligation to determine whether the restriction contained in this Section will limit any particular conversion hereunder and to the extent that the Holder determines that the limitation contained in this Section applies, the determination of which portion of the shares of Preferred Stock are convertible shall be the responsibility and obligation of the Holder.  The provisions of this Section may be waived by a Holder (but only as to itself and not to any other Holder) upon not less than 61 days prior notice to the Company. Other Holders shall be unaffected by any such waiver.

 

  

15

  

 

(e) Record Holder. The person or persons entitled to receive shares of the Common Stock issueable upon conversion of shares of the Preferred Stock shall be treated for all purposes as the record holder or holders of such shares of the Common Stock on the Conversion Date.

(f) Fractional Shares. The Company shall not be required to issue any fraction of a share of the Common Stock upon any conversion. All shares of the Common Stock, including fractions thereof, issue able upon conversion of more than one share of the Preferred Stock shall be aggregated for purposes of determining whether the conversion would result in the issuance of a fraction of a share of the Common Stock. If, after such aggregation, the issuance would result in the issuance of a fraction of a share of the Common Stock, the Company shall round such fraction of a share of the Common Stock up or down to the nearest whole share.

(g) Re-issuance of Certificates. In the event of a conversion of less than all of the shares of the Preferred Stock represented by a particular Preferred Stock Certificate, the Company shall promptly cause to be issued and delivered to the holder of such Preferred Stock a new Preferred Stock Certificate representing the remaining shares of the Preferred Stock which were not corrected.

5. Reservation of Shares. The Company shall, so long as any of the shares of the Preferred Stock are outstanding, reserve and keep available out of its authorized and unissued shares of the Common Stock, solely for the purpose of effecting the conversion of the shares of the Preferred Stock, the number of shares of the Common Stock as shall from time to time be sufficient to affect the conversion of all of the outstanding shares of the Preferred Stock.

6. Lost or Stolen Certificates. Upon receipt by the Company of evidence satisfactory to the Company of the loss, theft, destruction or mutilation of any Preferred Stock Certificates representing shares of the Preferred Stock, and, in the case of loss, theft or destruction, of any indemnification undertaking or bond, in the Company's discretion, by the holder to the Company and, in the case of mutilation, upon surrender and cancellation of the Preferred Stock Certificate(s), the Company shall execute and deliver new Preferred Stock Certificate(s) of like tenor and date.

 

7. Voting Rights.  Except as otherwise provided herein and as otherwise required by law, the Preferred Stock shall have no voting rights.  However, so long as any shares of Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the Holders of a majority of the shares of the Preferred Stock then outstanding, (a) alter or change adversely the powers, preferences or rights given to the Preferred Stock or alter or amend this Certificate of Designation, (b) authorize or create any class of stock ranking as to dividends or distribution of assets upon a Liquidation (as set forth in Section 3) senior to or otherwise pari passu with the Preferred Stock, (c) amend its certificate or articles of incorporation or other charter documents so as to affect adversely any rights of the Holders, (d) increase the authorized number of shares of Preferred Stock, or (e) enter into any agreement with respect to the foregoing.

  

16

  

 

NOTICE OF CONVERSION

 

(To be Executed by the Registered Holder

in order to convert shares of Preferred Stock)

The undersigned hereby elects to convert the number of shares of Series E Convertible Preferred Stock indicated below, into shares of common stock, par value $.00001 per share (the “Common Stock”), of BioNeutral Group, Inc., a Nevada corporation (the “Company”), according to the conditions hereof, as of the date written below.  If shares are to be issued in the name of a person other than undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith.  No fee will be charged to the Holder for any conversion, except for such transfer taxes, if any.  By tendering this Notice of Conversion, the undersigned hereby covenants to comply with the prospectus delivery requirements under the Securities Act of 1933, as amended, applicable to it with respect to resales of the shares of Common Stock issuable upon the conversion requested hereby pursuant to a registration statement and, in connection therewith, covenants that, unless otherwise specified below, such shares have been or are intended to be sold in ordinary brokerage transactions.

 

	 Conversion calculations:      	 	 
	 	 Date to Effect Conversion	 
	 	 	 
	 	 	 
	 	 Number of shares of Preferred Stock owned prior to Conversion	 
	 	 	 
	 	 	 
	 	 Number of shares of Preferred Stock to be Converted	 
	 	 	 
	 	 	 
	 	 Stated Value of shares of Preferred Stock to be Converted	 
	 	 	 
	 	 	 
	 	 Number of shares of Common Stock to be Issued	 
	 	 	 
	 	 	 
	 	 Applicable Conversion Price	 
	 	 	 
	 	 	 
	 	 Number of shares of Preferred Stock subsequent to Conversion	 
	 	 	 
	 	 	 
	 	 Signature	 
	 	 	 
	 	 	 
	 	 Name	 
	 	 	 
	 	 	 
	 	 Address	 

 

Accepted and Agreed:

BioNeutral Group, Inc.

By:_____________________________________

     Name:

     Title:

 

 

 

17f8k103111ex10v_bioneutral.htm

Exhibit 10.5

 

Parties

Bioneutral Group, Inc, a corporation organized under the laws of Nevada, with an executive office at 211 Warren Street, Newark, New Jersey 07103, Attn:  Raj Pamani Bioneutral Laboratories Corporation USA a corporation organized under the laws of Delaware, 211 Warren Street, Newark, New Jersey 07103, Attn:  Raj Pamani –  together referred to as BONU

And

Vinfluence Pty Ltd ACN 147 137 899 of Address Level 14 No 1 Alfred Street Sydney, New South Wales, Australia referred to as Licensee

AGREEMENT TO LICENSE INVENTION

ON THE BASIS THAT –

A.           Bonu owns valuable intellectual property rights relating to certain chemical formulations known as “Ygiene and Ogiene”  and applications for Ygiene and Ogiene capable of cleaning, deodorizing, neutralizing noxious chemicals and /or killing micro organisms.

B.           Licensee wishes to obtain from BONU an exclusive license of the Intellectual Property to manufacture, distribute, promote, use and sell Ygiene and Ogiene for all applications in the Territory  and a non exclusive license in the OPTIONED TERRITORY, which shall become exclusive upon the exercise of an option related thereto, and wishes to use the intellectual property of BONU for such purpose.

C.           Subject to the terms and conditions of this Agreement, BONU agrees to grant Licensee such right and license to use said intellectual property.

AGREEMENT TO LICENSE INVENTION

THE PARTIES AGREE –

1 DEFINITIONS AND INTERPRETATION

1.1           Affiliate means any person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, another person. A person shall be deemed to control another person for the purposes of this definition, if the first such person possesses, directly or indirectly, the power to appoint a majority of the directors of the second person, or to otherwise direct or cause the direction of the management or policies of the second person, whether through the ownership of voting securities, by contract or otherwise.

 

1.2           Authorized Ex-Territory Manufacturer means BONU or a manufacturer contracted to, or licensed by, BONU outside of the Territory.

 

1.3           Authorized Ex-Territory Purchaser means BONU or a licensee of BONU authorized by BONU to purchase Licensed Product from Licensee.

 

  

1

  

 

1.4           Commencement Date means the date of this Agreement.

1.5           Confidential Information means: all information concerning Ygiene and Ogiene including all test data and  information on file with the EPA, Toxcel, Keystone and the US Patent Office, which represents all the current information necessary to manufacture the products and to establish Quality Assurance and Quality Control programs  relating, directly or indirectly, to the Licensed Property and any Improvement.

1.5.1        any information that is, by its nature, confidential or that BONU advises Licensee in writing to be confidential; but does not include any information that is in the public domain or would, in the ordinary course of commercialization would be made known to the relevant market.

1.5.2        The parties agree to exclude from the terms of this Agreement;    any information that is, at or prior to the date of disclosure, information already in the public domain or publicly available through no fault of (a) Licensee, (b) any of its Affiliates (c) any subcontractor or sublicense of Licensee or its Affiliates or (d) any agent or representative of Licensee, any of its Affiliates, or any of its or their subcontractors or sublicensees; is, at the date of disclosure, already properly in the possession of Licensee from sources other than BONU and/or its Affiliates (provided, however, that this clause 1.5.2 shall not apply or extend to any Acquired Trade Secrets or Acquired Confidential Information).

1.6           Copyright means the copyright in all original copyright works relating to any Licensed Property or any Improvement.

 

1.7           Exclusive in respect of a right granted under this Agreement means the grantor shall not exercise that right and shall not authorize others to exercise that right.

 

1.8           Existing Patents means, collectively, the Patents, if any, that, at the relevant time, are pending or have been granted or issued under or with respect to the patent applications that are described in First Schedule attached hereto.

 

1.9           Force Majeure means circumstances beyond the reasonable control of a party that result in such party being unable to observe or perform on time an obligation under this Agreement. Such circumstances include, but are not limited to:

 

1.9.1        forces of nature, lightning strikes, earthquakes, floods, storms, explosions, fires and any natural disaster; or

 

1.9.2        acts of war, acts of public enemies, terrorism, riots, civil commotion, malicious damage, sabotage and revolution.

 

1.10         Improvement means any improvement to or development, modification or derivative of any Licensed Product or any application of any Licensed Product and includes:

the Patents; registered and unregistered designs and design applications; registered and unregistered trademarks; copyrights, including the Copyright; the Confidential Information; manufacturing know-how and other Trade Secrets; all regulatory filings and test results, and any and all intellectual property rights, however described, set forth on the Second Schedule to the Transfer Agreement.

  

2

  

1.10.1     any beneficial modification of a component or material useful in any Licensed Product or in the manufacture or use of any Licensed Product;

 

1.10.2      any development relating to an apparatus or process for producing or utilizing any Licensed Product; and

1.10.3     any new or alternative use for any Licensed Product.

 

1.11         Intellectual Property means all intellectual property rights relating to the Licensed Property, any Licensed Products, including, without limitation to the Confidential Information, all technical information, research and development details, specimen samples for product analysis, prototypes, test data and reports, manufacturing methods, designs, ingredients, compositions, raw materials, details of raw materials suppliers, costs, pricing, business plans, development plans, marketing and distribution plans, lab books, note books, documents, records and similar material in any form whatsoever, all secret information, data, drawings, specifications, documentation, know-how and commercially sensitive information relating, directly or indirectly, to any Improvement concerning or relating to the Licensed Property, Licensed Products or any of the Confidential Information, including any and all applications for approval to introduce the products into commerce by regulatory agencies including the United States EPA/FDA or similar regulatory agencies in and outside the territory.

 

1.12        Licensed Country means the government of any country currently located in the Territory and the departments, branches, commissions, agencies and other divisions and subdivisions of such government.

 

1.13         Licensed Products means any product or process that:

 

1.13.1           is or utilizes any Licensed Property or any Improvement and/or

 

1.13.2 the manufacture, use or sale of which but for the licenses granted herein, would constitute an unauthorized activity with respect to the Intellectual Property (including, for the avoidance of doubt, the Patents).

 

1.14           Licensed Property means the proprietary chemical formulations known as Ygiene and Ogiene in all its iterations or derivations, capable of neutralizing noxious chemicals and/or killing harmful microbes, as listed in the Third Schedule (which Schedule shall be amended, supplemented and updated as iterations are developed or perfected) and applications for such formulations.

1.15         Patents means:

 

1.15.1 those granted patents and patent applications, short particulars of which are set out in the First Schedule of this Agreement, together with any patents granted pursuant to such applications;

 

1.15.2 any granted patents or patent applications of BONU claiming priority from those in such First Schedule; and

 

1.15.3 any patent applications filed by or on behalf of BONU after the Commencement Date in relation to any aspect of any Licensed Product, together with any patents granted pursuant to such applications, together with all divisional, continuations, continuations-in-part, reissues, re-examinations and extensions of such patents and patent applications.

 

1.16         Territory means the geographic area currently comprised of Australia, Brunei, Cambodia, China, Cook Islands, East Timor, Federated States of Micronesia, Fiji, French Polynesia, Hong Kong, Indonesia, Israel, Japan, Kiribati, Laos, Malaysia, Marshall Islands, Myanmar, Nauru, New Caledonia, New Zealand, Niue, Palau, Papua New Guinea, Pitcairn Islands, Samoa, Singapore, Solomon Islands, South Korea, Taiwan, Thailand, Tokelau, Tonga, Tuvalu, Vanuatu, Vietnam, and Wallis and Futuna, which geographic area shall be unaffected by any change after the date hereof in (a) the name of any of the foregoing listed countries or (b) the boundaries of any of such countries.

OPTIONED TERRITORY shall mean all of the countries in Europe as defined by Wikipedia as of the date of this Agreement.

  

3

  

 

1.17         Trademarks means the registered and unregistered trademarks referred to in the Second Schedule and any variation on improvement to such trademarks including any future trademarks used concerning or referring to the Licensed Product.

 

1.18         Trade Secrets means:

 

1.18.1 all secret information and materials to the extent the same relate, directly or indirectly, to any Licensed Product including, but not limited to, all technical information, research and development details, specimen samples for product analysis, prototypes, test data and reports, manufacturing methods, designs, ingredients, compositions, raw materials, details of raw materials suppliers, costs, pricing, business plans, development plans, marketing and distribution plans, lab books, note books, documents, records and similar material in any form whatsoever; and

1.18.2 all secret information, data, drawings, specifications, documentation, know-how and commercially sensitive information relating, directly or indirectly, to any Improvement.

1.19          In this Agreement, unless the context otherwise requires: references to sections, paragraphs, sub-clauses, clauses, exhibits and schedules are to sections, paragraphs, sub-clauses, clauses, exhibits and schedules of this Agreement; all headings in this Agreement have been inserted for convenience only and do not limit or govern its construction or interpretation; words importing the singular are deemed to include the plural and vice versa; words importing any gender are deemed to include all other genders; and words importing persons are deemed to include all associations, authorities and bodies, corporate or unincorporated; references to any legislation, or to any section or provision of any legislation, include any statutory modification or re-enactment or any substituted statutory provision and rules, regulations, laws and other statutory instruments issued or promulgated under or pursuant to such legislation; references to the words “including” and “include” are to be construed without limitation; and this Agreement will not bind either party until it has been signed by both parties.

 

2 GRANTOFRIGHTS

 

2.1           Subject to the other terms and conditions of this Agreement, BONU grants to Licensee during the term of this Agreement the Exclusive, perpetual license and right to exploit the Intellectual Property to manufacture, distribute, promote, use and sell Licensed Products in the Territory, subject to the provisions of this Agreement. BONU further grants to Licensee during the term of this Agreement a license and right to import Licensed Products into the Territory and Optioned Territory from an Authorized Ex-Territory Manufacturer and to export Licensed Products outside of the Territory and Optioned Territory to an Authorized Ex-Territory Purchaser.  In addition, BONU grants to Licensee during the term of this Agreement a non-exclusive license and right to exploit the Intellectual Property to manufacture, distribute, promote, use and sell Licensed Products in the Optioned Territory and to the United States Military, subject to the provisions of this Agreement.

  

4

  

 

2.2           Subject to the other terms and conditions of this Agreement, BONU grants to Licensee during the term of this Agreement the Exclusive, license and right to exploit the Trademarks to manufacture, distribute, promote, use and sell Licensed Products in the Territory, subject to the provisions of this Agreement.  In addition, BONU grants to Licensee during the term of this Agreement a non-exclusive license and right to exploit the Trademarks to manufacture, distribute, promote, use and sell Licensed Products in the Optioned Territory and to the United States Military (“US Military”), subject to the provisions of this Agreement.

2.3           The rights granted to Licensee in clause 2.1 and 2.2 may not (except as expressly permitted under clause 21 below) be assigned by Licensee in whole or part without the express written consent of BONU.

2.4           Licensee will provide to BONU within fourteen (14) days of the grant of any sub-license or sub-contract, a true and complete copy of the document recording the terms of such sub-license or sub-contract; Licensee will use reasonable endeavors to ensure that each sub-licensee or sub- contractor duly observes and performs its obligations and undertakings under the relevant sub-license or sub-contract; each sub-license or sub-contract will expire or terminate with the expiration or termination of this Agreement, for any reason whatsoever; no sub-license or sub-contract shall grant exclusivity unless such grant of exclusivity is subject to all qualifications and limitations provided for herein with respect to any exclusivity granted to Licensee; each sub-license or sub-contract of the right to distribute, promote, use and/or sell Licensed Products under this Agreement shall contain the provisions set forth in Exhibit A hereto (with such revisions as the parties may from time to time reasonably mutually agree), each sub-license or sub-contract of the right to manufacture Licensed Products under this Agreement shall contain the provisions set forth in Exhibit B hereto (with such revisions as the parties may from time to time reasonably agree). and any attempt to assign all or any portion of such rights without the express written consent of BONU shall be null and void and of no force or effect. Unless Licensee is a party to a listing agreement with a stock exchange, which is recognized as such in the country in which any such stock exchange operates, the sale and acquisition of all or a majority of the shares or stock of Licensee will be deemed an assignment for the purpose of this clause 2.3.  In the event that the Licensee is listed in the United States, a recognized stock exchange shall be a market equal to at least the OTC Bulletin Board.

 

2.5           Licensee may grant a sub-license or sub-contract in respect of the rights granted in clause 2.1 and 2.2, provided that each and all of the following conditions have been met: Licensee will not cause or permit any sub-licensee or sub-contractor to breach, and will take all reasonably necessary steps to prevent each sub-licensee and sub-contractor from breaching, such sub-licensee's or sub-contractor's obligations with respect to the provisions referred to in this agreement.

 

  

5

  

 

2.6           Except with respect to the Optioned Territory and the United States Military, Licensee agrees that it will not sell, distribute or supply, or cause, allow or permit any sub- licensee, subcontractor, wholesaler or other distributor, agent or representative to sell, distribute or supply, any Licensed Products to any third party (a) that is located outside the Territory other than to an Authorized Ex-Territory Purchaser or (b) that is located inside the Territory if Licensee suspects or believes, or has reasonable cause or grounds to suspect or believe that, any Licensed Products sold, distributed or supplied to such third party might either be (i) used by such third party outside the Territory or (ii) subsequently resold or distributed by such third party (or any agent or representative of such third party) outside the Territory. Licensee shall not sell, distribute or supply any of the Licensed Products to any third party other than an Authorized Ex- Territory Purchaser unless such third party has executed and delivered to Licensee a written agreement that contains the provisions set forth in Exhibit A hereto (with such revisions as the parties hereto may from time to time reasonably agree). Furthermore, Licensee agrees that it will not without the prior written consent of BONU (which consent will not unreasonably be withheld in the case of a branch, subsidiary or associate of a reputable manufacturer based in the Territory) manufacture, or cause, allow or permit any sub-licensee or subcontractor (other than an Authorized Ex-Territory Manufacturer) to manufacture any Licensed Products outside the Territory. Licensee shall not cause, allow or permit any sub-licensee or subcontractor to manufacture any Licensed Products unless such sub-licensee or subcontractor has executed and delivered to Licensee a written agreement that contains the provisions set forth in Exhibit B hereto (with such revisions as the parties hereto may from time to time reasonably agree).

 

2.7           Licensee will not cause any such third party to breach, and will take all reasonable steps to prevent each such third party from breaching, such third party's obligations with respect to the provisions referred to in clause 2.5 above to be included in each contract with such third party or any similar provisions having like effect.

 

2.8           In view of the Exclusive nature of this agreement, except as it relates to the Optioned Territory and the United States Military, for so long as this Agreement is in force Licensee shall not, and shall not allow or permit any Affiliate to, enter into direct or indirect competition outside the Territory with BONU or any of its Affiliates in respect of the manufacture, sale, distribution, supply or marketing of any products that compete with any of the Licensed Products.

 

2.9           Notwithstanding anything contained herein to the contrary, Licensee shall be entitled to sell, distribute or supply Licensed Products to any Licensed Country  but Licensee shall not be liable or responsible for any use of any Licensed Products outside the Territory, the Optioned Territory or to the United States Military, by any Licensed Country.

 

2.10         Nothing in this Agreement shall constitute any representation that the Patents shall proceed to grant or, if granted, shall be valid or that the Licensed Products do not fall within the scope of any intellectual property rights of any third party.

 

2.10.1      Notwithstanding anything contained herein to the contrary, this Agreement shall not apply or extend to, and no Exclusive right shall apply or extend to, any Patent that has expired, any Trade Secret that has become publicly available (through no fault of (a) Licensee, (b) any of its Affiliates (c) any subcontractor or sublicensee of Licensee or its Affiliates or (d) any agent or representative of Licensee, any of its Affiliates, or any of its or their subcontractors or sublicensees).

 

2.10.2 While this agreement is in effect BONU agrees that it will not communicate with any of the end users, suppliers, distributors, manufacturers, employees or consultants of the Licensee without the express written permission of Licensee.  Nor will BONU use or disclose any of the confidential commercial information provided by Licensee during the course of this agreement.

 

  

6

  

 

2.11        Consideration for the exclusive license and distribution agreement in the Territory shall be:

2.11.1 The parties agree that good and valuable consideration has been received and neither party shall dispute this fact.  In addition, US$1,000.00 paid at the time the Licensed Property and other Confidential Information is passed to the Licensee so that the Licensed Products can be manufactured.  This information shall include a complete copy of the application submitted by BONU to the US EPA, a copy of the formulation as provided to its regulatory advisor, Toxcel, all manufacturing instructions provided to its manufacturer, Keystone, and copies of the patent applications which have been filed with the United States Government.

 

2.11.2 a royalty payment to BONU on all net sales made by the Licensee in its Territory.  Such payment to be made twice annually no later than 60 days after the end of the period being the financial year end and the financial half year of the Licensee.  No later than 30 days following the conclusion of the relevant period the Licensee will provide BONU a statement showing all sales which occurred for the preceding 6 months.  Within 14 days of being provided the sales statement BONU will issue to Licensee an invoice for the royalty payment. Sales are calculated once and as they are reflected on the books of Licensee without sales tax or any other transaction or importation tax, less any returns or bad debts.  Royalties are calculated and payable on the basis of 5% of the first $1 million in sales, 4% for the next $1 million in sales and 3% thereafter.

For the Optioned Territory and US Military prior to the Option being exercised – a royalty payment calculated as in 2.11.2 above.

 

2.11.3 Commencing the beginning of year 4 from the signing of this Agreement and receipt of all Confidential Information, the Licensee will pay to BONU the greater of either the calculated royalty (as shown in 2.11.2 above) or $100,000 per year.  Commencing the beginning of years 6 – 10, the greater of either the calculated royalty, as set out in 2.11.2 above, or $400,000 per year.

2.11.4 royalty payments described in 2.11.2 and 2.11.3 will not commence until regulatory approval is received for Ygiene 206 by BONU from the US EPA and State regulators and the Licensee receives a similar approval for its Territory.

2.11.5 LEFT BLANK

 

  

7

  

 

 

2.11.6 Licensee will provide copies of all marketing and sales information developed for the Territory when reasonably requested by BONU.

2.11.7 Licensee will provide BONU, copies of all tests performed on Licensed Products when reasonably requested by BONU.

2.11.8 Licensee intends to invest in excess of US$2 million to develop the Licensed Product for exploitation within the Territory.

2.11.9 Licensee reserves the right to sell the marketing material it creates to other licensees in other territories for their use of such collateral in their territory e.g. brand names, logos, slogans and other marketing material.

2.12        Optioned Territory.  Licensee shall have the option (“Option”), at its sole discretion, to convert the non-exclusive license in the Optioned Territory to an Exclusive license.

2.12.1  Licensee shall exercise the Option by giving BONU written notice of its intention to exercise the Option.  Licensee shall be entitled to exercise the Option, at its sole discretion, at any time within 1 year from the date of this Agreement.  Immediately upon Licensee’s exercise of the Option, all of the terms and conditions of Sections 2.2 through 2.10 shall, in addition to the Territory, be applicable to the Optioned Territory. 

2.12.1a/  If the Option for the Optioned Territory is not exercised prior to 1 year from the date of this Agreement, it shall remain non exclusive and subject to termination by BONU with 6 months prior written notice.  Sales to the US Military shall also be non-exclusive and subject to termination with 6 months prior written notice.

If BONU terminates the non exclusive rights in the Optioned Territory, and the Licensee does not exercise the Option for the Optioned Territory, or the non exclusive rights relative to the US Military, or any non exclusive agreement arising from this Agreement, BONU shall compensate Licensee for its investment of time and money by paying an ongoing fee of 12.5% of all Licensee’s sales of any Licensed Products to any and all distributors or end users during an exclusive or non exclusive period.  Such payment to be due and payable within 15 business days of the end of every calendar quarter and which shall expire when all of the purchasers cease to purchase products containing the Confidential Information.   The aforementioned obligation will not be offset by any other fees paid to distributors or agents within the non exclusive or exclusive Territory or by any license to another party or by any sale of the business or assets of BONU or by any change of trademark or brand applied to the products.  In the event of any such termination of the non-exclusive rights to the Optioned Territory or the US Military, BONU shall be required to provide Licensee with a detailed monthly statement identifying all sales of Licensed Products to any and all distributors and end users within 15 days of the end of each month.  Additionally, in the event of any such termination, BONU shall be required to promptly provide Licensee with copies of any and all communications between the purchaser/end user and BONU, its distributors, agents, licensees or successors.

 

  

8

  

 

2.13         Consideration for the exclusive license and distribution agreement in the Optioned Territory shall be:

2.13.1 US$1,000,000.

2.13.2 a royalty payment to BONU on all net sales made by the Licensee in the Optioned Territory.  Such payment to be made twice annually no later than 60 days after the end of the period being the financial year end and the financial half year of the Licensee.  No later than 30 days following the conclusion of the relevant period the Licensee will provide BONU a statement showing all sales which occurred for the preceding 6 months.  Within 14 days of being provided the sales statement BONU will issue to Licensee an invoice for the royalty payment. Sales are calculated once and as they are reflected on the books of Licensee without sales tax or any other transaction or importation tax, less any returns or bad debts.  Royalties are calculated and payable on the basis of 5% of the first $1 million in sales, 4% for the next $1 million in sales and 3% thereafter.

2.13.3 Commencing the beginning of year 4 following 2.13.1 the Licensee will pay to BONU the greater of the calculated royalty (as shown in 2.13.2 above) or $500,000 per year, which shall increase to $1,500,000 per year  commencing in year 6 and continuing through year 10.

2.13.4 Royalty payments described in 2.13.2 and 2.13.3 will not commence until regulatory approval is received by BONU from the US EPA and State regulators for Ygiene 206 and the Licensee receives a similar approval in its Optioned Territory.

2.13.5 Licensee will provide copies of all marketing and sales information developed for the Territory when reasonably requested by BONU.

2.13.6 Licensee will provide BONU, copies of all tests performed on Licensed Products when reasonably requested by BONU.

2.13.7 Licensee intends to invest in excess of US$2 million to develop the Licensed Product for exploitation within the Optioned Territory.

2.13.8 Licensee reserves the right to sell the marketing collateral it creates to other licensees in other territories for their use of such collateral in their territory e.g. brand names, logos, slogans and other marketing material.

2.14         Board Observer.  During the Initial Term (defined below) and during any renewal of the Initial Term (defined below), License shall be entitled to designate a person, which may change from time to time, to observe all board of directors meetings (“Observer”), either in person or via teleconference at Licensee’s discretion.  Licensee shall give the Company at least 48 hours notice as to the name of Observer that will attend the Board meeting, prior to each such meeting.  The Licensee shall be entitled to receive notice of each meeting of the Company’s board of directors (“Board”) at the same time as members of the Board receive such notice.  The Observer shall be entitled to attend any and all Board meetings, however, the Observer shall not be entitled to vote at any such meeting and shall be responsible for its own costs and expenses in attending any such meetings.  The Observer will sign any documents reasonably requested by the Company in connection with maintaining the confidential nature of the matters discussed at any such meetings, however, prior to each meeting the Observer shall be notified as to whether the Board intends to discuss any material non-public information at any such meeting.  If the Observer is unable to attend any such meeting in person or via teleconference, upon Observer’s request the Observer shall be entitled to receive a copy of all minutes of any such Board meeting.

 

  

9

  

 

3 DURATION OF AGREEMENT

3.1           This Agreement shall expire on the date that is10 years from the date of this Agreement (“Initial Term”). At the end of the Initial Term, this Agreement shall automatically renew for an additional ten years on the same terms and conditions as set forth in this Agreement, except in the event that either BONU or Licensee provide the other party with six months prior written notice of its intention to not extend the Initial Term of this Agreement. This Agreement shall terminate upon the occurrence of a material breach by the Licensee which is not cured within 12 months of written notice by BONU to Licensee and which has been adjudicated in favor of BONU in accordance with the dispute provisions of this agreement.

Upon termination of this Agreement, all Confidential Information will revert to BONU and all territory effected by the termination will be considered non exclusive and the terms and conditions of clause 2.12.1a/ shall apply.

4 FEES AND EXPENSES

 

4.1           Licensee and/or its permitted sub-licensees will be responsible for the payment of all direct expenses associated with laboratory testing for the purpose of research and development of new applications for Licensed Products within the Territory or Optioned Territory.  Any and all amounts are at the discretion of the Licensee.

 

4.2           Licensee and/or its permitted sub-licensees will pay for all direct expenses associated with obtaining regulatory approvals for manufacturing, marketing and/or sale of the Licensed Products in the Territory or Optioned Territory, for all present and future applications of Licensed Products within the Territory.  BONU must pay for all expenses associated with the regulatory approvals for the manufacture of the Licensed Products with the US EPA and US FDA.

 

4.3   INTENTIONALLY LEFT BLANK

 

5      LICENSEE’S PERFORMANCE OBLIGATIONS

 

5.1           All Licensed Products that are manufactured or marketed by or on behalf of Licensee shall be of merchantable quality; and if practical, each batch or the packaging thereof of each Licensed Product manufactured by or on behalf of Licensee shall contain marker(s) so as to enable Licensee to determine the batch (and the source of each batch) from which any Licensed Product is derived. BONU or its duly authorized agent shall be entitled to inspect Licensed Products manufactured by Licensee, including, but not limited to, entering Licensee’s premises for the purpose of inspecting the manner of manufacture, quality control systems and the Licensed Products, provided that BONU shall give at least 7 days written notice of its intention to inspect before arriving at Licensee’s premises.

 

 

  

10

  

 

5.2           Licensee shall at all times indemnify and keep indemnified BONU against all or any costs, claims, charges, liabilities, damages or expenses (including, without limitation, reasonable attorneys' fees and other costs of investigation, defense, enforcement and/or appeal) incurred by BONU or for which BONU may become liable, in respect of Licensed Products manufactured or marketed by or on behalf of Licensee; provided, however, that Licensee shall not be obligated hereunder to indemnify BONU with respect to any costs, claims, charges, liabilities, damages or expenses arising from any breach by BONU of any of its representations or warranties hereunder or if the licensed invention or trade secret is found to breach the intellectual property rights of any other.

6    BONU’S PERFORMANCE OBLIGATIONS

6.1           BONU shall use its best efforts to obtain, and for the Term maintain, the registration of Patents, and must maintain Trademarks, confidentiality of the Confidential Information, all regulatory fillings, the goodwill, reputation of the Licensed Products in the United States and Ex-Territory.

6.2           BONU shall at all times indemnify and keep indemnified Licensee against all or any costs, claims, charges, liabilities, damages or expenses (including, without limitation, reasonable attorneys' fees and other costs of investigation, defense, enforcement and/or appeal) incurred by Licensee or for which Licensee may become liable, in respect of Licensed Products manufactured or marketed by or on behalf of Licensee with respect to any costs, claims, charges, liabilities, damages or expenses arising from any breach by BONU of any of its representations or warranties hereunder or if the licensed invention is found to breach the intellectual property rights of any other.

 

6.3           BONU shall provide electronic copies of all test data produced when testing its products.  Such data will be provided within 10 days of receipt.

 

6.4           BONU shall provide copies of all marketing material associated with the sale of its products within 10 days of it being available to the public.

 

AGREEMENT TO LICENSE INVENTION

7 MANUFACTURING

 

7.1           Licensee and/or its permitted sub-licensees will bear all costs for manufacturing Licensed Products in the Territory, Optioned Territory and to the United States Military.

 

7.2           Licensee will ensure Licensed Products are manufactured strictly in accordance with BONU confidential procedures and specifications relating to the Licensed Products as advised by BONU from time to time; provided, however, that if such confidential procedures and specifications are more onerous to Licensee than those confidential procedures and specifications normally imposed in Australia or such other place of manufacture in the territory,  or such other location within the territory on chemical manufacturers by intellectual property owners, then Licensee shall comply with such procedures and specifications to the extent normally imposed; and, provided further, that nothing in this clause 7.2 shall diminish, reduce, limit or otherwise affect Licensee’s obligations of confidentiality elsewhere provided herein).

 

  

11

  

 

7.3           While this Agreement is in force, Licensee will not acquire Licensed Property from any source other than BONU

8 RESEARCH AND DEVELOPMENT

 

8.1           Each party (“first party”) shall disclose to the other party not less than once every calendar

quarter during the term of this Agreement, all information in its possession or control (other than commercially sensitive operating financial information) relating to the research and development and testing of Licensed Products by or for the first party; and any other activities (including marketing, distribution and commercialization) undertaken by the first party in connection with Licensed Products.

9 PROVISION OF TECHNICAL ASSISTANCE UPON REQUEST

 

9.1           BONU will make available to Licensee any know-how relating to the manufacture of any of the Licensed Products and that is necessary for manufacture.

9.2           Know-how disclosed under this Agreement is subject to the confidentiality obligations in clause 13 of this Agreement.

10 INTELLECTUAL PROPERTY OWNERSHIP AND IMPROVEMENTS

10.1         Licensee acknowledges and agrees that, as between Licensee and BONU, BONU warrants that it is the exclusive owner of all the Confidential Information and Patents.

10.2         In the event of the failure of any of the Patents, or any of the technology embodied in the Trade Secrets being superseded, BONU shall be under no obligation to compensate Licensee.

10.3         Any and all Improvements devised, developed, created or otherwise obtained by Licensee or BONU and over which either has right of disposal, shall be promptly assigned, transferred and conveyed at the expense of the receiving party, provided that all rights to such Improvements shall, from the date the assignment, transfer or conveyance becomes effective, be automatically included as Intellectual Property licensed to Licensee under this Agreement.

11 MAINTENANCE OF PATENTS BY BONU

11.1         BONU shall use commercially reasonable efforts to prosecute to grant the patent applications listed on the First Schedule attached hereto (provided, however, that BONU shall have no obligation or liability in the event any patent for which application has been made or may hereafter be made is not granted or issued) and for timely payment of renewal fees in order to maintain such patents as are or have been granted to BONU.

 

11.2         Notwithstanding clause 10.1, BONU may at its sole discretion choose to renew or abandon all or any of the Patents, provided that it shall notify Licensee of its intention not to renew or to abandon any Patent in the Territory at least one month prior to the date on which any right there under will lapse as a result of non-renewal or abandonment. Upon receipt of such notice, Licensee shall have the right to renew or continue with the relevant Patent(s) at its own cost, and BONU shall promptly assign to Licensee all BONU’s rights in and title to such Patent(s). From the date of assignment, this Agreement shall be varied by the exclusion of such Patent(s) from the definition of Existing Patents and Patents, as the case may be.

 

  

12

  

 

12 INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS

12.1         Promptly after becoming aware of same, Licensee shall give written notice to BONU of any infringement or threatened infringement within the Territory or Optioned Territory of any Trade Secret, Patent or any other Intellectual Property.

 

12.2         Promptly after becoming aware of same, BONU shall give Licensee written notice of any infringement or threatened infringement of any Trade Secret, Patent or any other Intellectual Property within the Territory or Optioned Territory.

 

12.3           In the event of any such infringement or threatened infringement of any Trade Secret, Patent or other Intellectual Property in the Territory or Optioned Territory, the parties shall consult to decide the best way to respond. If the parties cannot agree within thirty (30) days of such notice being given, Licensee shall have the right, but not the obligation, to take action against any relevant third party on its own account or on behalf of BONU, and Licensee shall be entitled to retain for its absolute benefit all damages, costs or other expenses awarded in such proceedings. BONU shall give all reasonable assistance at Licensee’s expense to facilitate any proceedings by Licensee including joining such proceedings as a party if requested by Licensee to do so. BONU’s written consent must be obtained if any action or proposed settlement by Licensee under this clause 12.3 involves the making of any statement (whether express or implied) concerning the validity of any Trade Secrets, Patents, Intellectual Property or any liability of BONU. If Licensee does not wish to take any action against the relevant third party, then BONU may take such action, and Licensee shall give all reasonable assistance to BONU at BONU’s expense to facilitate such proceedings, and BONU shall be entitled to retain for its absolute benefit all damages, costs or other expenses awarded in such proceedings.

12.4         Subject to clause 12.4.1 below, BONU shall indemnify Licensee against all costs, (including Licensee’s reasonable legal costs), expenses, damages or liability awarded against Licensee or incurred by Licensee under any final judgment in proceedings brought by any third party against Licensee to the extent such judgment has determined that Licensee's use or practice of an invention under any Existing Patent in the manufacture, distribution, promotion, use or sale of any Licensed Products infringes the patent of any third party.

 

12.4.1     BONU shall not indemnify Licensee unless:

 

12.4.1.1     BONU is given notice in writing as soon as practical of any infringement, suspected infringement or alleged infringement by Licensee;

 

12.4.1.2     Licensee grants BONU the sole right to conduct the defense of the proceedings mentioned in clause 12.3, including negotiations for settlement or compromise prior to or during such proceedings (provided, however, that BONU may not enter into any settlement or compromise on behalf of Licensee without its prior written consent; and

 

12.4.1.3 Licensee promptly and fully provides such assistance as BONU reasonably requests to settle or conduct the defense of such proceedings. 

 

12.4.2     With respect to any patent that may hereafter issue and be granted to BONU with respect to any Licensed Product (other than any Existing Patent), BONU will advise Licensee of any third party intellectual property relating to the practice of this invention disclosed and claimed in such patent that is known to BONU. Licensee will make its own decision with respect to its use or practice of such patent and to the extent that disclosure has been made as aforesaid will assume all risks associated therewith, and to the extent that disclosure has been made as aforesaid BONU shall have no liability to Licensee with respect to such patent or the use or practice thereof, regardless of whether such patent or the use or practice thereof infringes or misappropriates the rights of any third party.

 

 

  

13

  

 

13 NON-DISCLOSURE OF CONFIDENTIAL INFORMATION

13.1         Licensee will treat all Confidential Information in the strictest confidence regardless of whether that Confidential Information was gained before or after the Commencement Date. Without limitation of the foregoing obligation and except as otherwise permitted by this Agreement, Licensee shall not, without the prior express written approval of BONU: 13.1.1 disclose, divulge, pass on or otherwise make available directly or indirectly all or part of the Confidential Information to any person or organization outside Licensee, other than a sub-licensee or sub-contractor pursuant to clause 2.4 or such other contractor to Licensee as required for the purposes of this Agreement or any prospective investor undertaking due diligence, all being pursuant to an obligation of confidentiality;

 

13.1.1.1  disclose all or part of the Confidential Information to any director, employee or advisor of Licensee unless both (a) such director, employee or advisor needs to know that Confidential Information for the purpose of this Agreement and (b) such director, employee or advisor has executed and delivered to Licensee a legally binding agreement imposing on such director, employee or advisor equivalent terms as to confidentiality and non-use of Confidential Information and ownership of intellectual property to those imposed on Licensee by this Agreement; or

 

13.1.1.2  use all or any part of the Confidential Information other than for the purpose of this Agreement or otherwise in any way that could reasonably be determined to be detrimental to or in conflict with the interests of BONU.

 

13.1.2 In the event that Licensee becomes legally compelled to disclose any of the Confidential Information to the courts of any competent jurisdiction, or to any government regulatory agency or financial authority, Licensee shall:

 

13.1.2.1  inform BONU as soon as is reasonably practicable; and

 

13.1.2.2   allow BONU a reasonable time to oppose or limit such disclosure or, at BONU’s request, seek to persuade the court, agency or authority to have the information treated in a confidential manner (where this is possible under the court, agency or authority’s procedures).

 

In the event that a protective order or other remedy is not obtained, Licensee shall furnish only that portion of the Confidential Information which is legally required to be furnished.

13.2        Licensee shall take all commercially reasonable actions to maintain the security of the Confidential Information, including:

 

13.2.1 securely storing the Confidential Information and restricting and controlling access to it;

 

13.2.2 refraining from taking all or any part of the Confidential Information in tangible form onto the premises of any third party (other than a sub-licensee or a sub-contractor pursuant to clause 2.4); and

 

  

14

  

 

 

13.2.3           Licensee will not cause or permit any of its employees, directors and advisors or any of its Affiliates, sub-licensees and sub-contractors to disclose, and will take all reasonable steps to prevent its employees, directors and advisors and its Affiliates, sub-licensees and sub-contractors from disclosing, all or any part of the Confidential Information to any unauthorized person or third party.

 

13.3         Licensee shall report to BONU any actual or presumed loss of secrecy in respect of the Confidential Information or any portion thereof (including the passing of all or any part of the Confidential Information into the public domain) as soon as possible after becoming aware that the same has occurred or is thought to have occurred, including any breaches of the security measures taken pursuant to clause

 

13.4         In the event of any actual, presumed or threatened breach of confidence or loss of secrecy, Licensee will refrain from disclosing or using (other than for the purpose of this Agreement) that Confidential Information for a further period of thirty (30) days from the date of notice, to give BONU an opportunity to seek urgent relief in the event that BONU is of the opinion that the relevant Confidential Information is not in the public domain or remains subject to the terms of this Agreement.

13.5         In the event Licensee is in any doubt whatsoever as to whether any information is Confidential Information, can be used for a particular purpose or can be disclosed to a particular third party, Licensee will treat that information as Confidential Information, refrain from using that information for that particular purpose or disclosing that information to that particular third party, unless BONU gives explicit written consent to do otherwise.

 

13.6         Licensee will, upon receipt of written notice from BONU of a perceived breach of any term of this Agreement, refrain from disclosing or using (other than for the purpose of this Agreement) the information identified in the notice for thirty (30) days from the date of the notice, to enable BONU to seek urgent relief.

14 RIGHTS GRANTED IN RESPECT OF TRADEMARKS

 

14.1         Licensee may apply the relevant trademark(s) set out in the Second Schedule to each and every Licensed Product as appropriate and include such trademark(s) in all promotional materials relating to any Licensed Products. BONU hereby grants Licensee a license during the term of this Agreement to use the trademark(s) set out in the Second Schedule in, but solely in, the Territory and Optioned Territory in relation to the Licensed Products.  BONU may, at its costs register the trademarks in the Territory.

 

15   BREACH AND TERMINATION

15.1         This Agreement may not be terminated except pursuant to clause 3.1. Damages and injunctive relief shall be the only remedies available to either party in the event of a breach of this Agreement by the other party.

16 NO BREACH FOR FORCE MAJEURE EVENTS

16.1         If either party is affected by Force Majeure, it will immediately notify the other party of the nature and extent of that Force Majeure.

 

16.2         Neither party will incur liability in respect of anything that might otherwise constitute a breach of this Agreement arising by reason of any Force Majeure notified to the other party. 16.3 If the Force Majeure in question prevails for a continuous period in excess of thirty (30) days, the parties will negotiate in good faith as to how the effects of the Force Majeure can be fairly and reasonably alleviated.

 

  

15

  

 

 

17 INVALID TERMS SEVERABLE

 

17.1         In the event that any term, condition or provision in this Agreement shall be determined by any competent authority to be invalid, unlawful or unenforceable to any extent, such term, condition or provision shall to that extent be severed from the remaining terms, conditions or provisions, which shall continue to be valid to the fullest extent permitted by law.

NOTICES

17.1

Any notice or other communication under this Agreement must be (i) in writing, (ii) marked for the attention of the person or office holder (if any) from time to time designated for the purpose by the recipient and (iii) directed either by email, facsimile or personal delivery to the addresses set out below:

 

If to BONU, to:                                     Bioneutral Group, Inc.

211 Warren Street

Newark, NJ 07103

Email: raj@bioneutralgroup.com

If to Licensee, to:                                Vinfluence Pty Ltd 

Level 14 No 1 Alfred Street Sydney

Australia 

Email: Wayne@noblemenventures.com 

No communication is effective until received. A communication will, however, be deemed to be received by the recipient:

 

18.2.1 in the case of an email or facsimile, on the business day on which it is dispatched or, if dispatched after 5.00pm (in the place of receipt) or on a non-business day, on the next business day after the date of dispatch; or

 

18.2.2 in the case of personal delivery, when delivered.

 

19 DISPUTES

19.1         The parties agree to notify each other immediately of any dispute and to initially attempt to settle any dispute arising out of this Agreement by full and frank discussions.

 

19.5         Nothing in this Agreement shall prevent a party from issuing or commencing judicial proceedings in relation to any dispute where the nature of the dispute is such that the party requires urgent interim relief or is seeking specific performance or other equitable relief.

 

19.6         The payment by either party of any amount hereunder shall not preclude such party from disputing its obligation hereunder to pay such amount or from disputing the amount paid.

 

  

16

  

 

 

20 INTENTIONALLY LEFT BLANK

20.1        This Agreement and any disputes arising in relation to it shall be governed by and construed in all respects in accordance with the laws of New South Wales, Australia without giving effect to the conflict of laws principles thereof, and shall be subject to the exclusive jurisdiction of the courts of Australia to which the parties hereby submit.

21 ASSIGNMENT

21.1         Except as permitted under clauses 21.2 , neither party shall, or shall be entitled to, assign, transfer or novate this Agreement or any of its rights, benefits, duties or obligations under this Agreement, and any effort to assign, transfer or novate this Agreement or any right or obligation hereunder except as expressly provided in clause 21.2 shall be null and void and of no force or effect.

21.2         Licensee may assign, transfer or novate this Agreement in whole or in part to a wholly owned subsidiary of Licensee or to a company whose shares are publicly traded, provided that (a) such assignment is accomplished pursuant to an assignment and assumption agreement and (b) such assignment shall not release or relieve Licensee of any of its duties, obligations and liabilities hereunder. BONU may, as part of or in connection with the transfer or assignment of all or substantially all of its business or assets, assign and transfer this agreement and all of BONU's rights, benefits, duties, liabilities and obligations hereunder to the transferee or assignee of such business or assets.

22 ANCILLARY PROVISIONS

22.1         This Agreement sets forth the entire agreement and understanding between the parties relating to the subject matter contained herein, and no modifications or amendments hereto shall be effective unless made in writing and signed by both parties.

22.2         Subject to any provision to the contrary, this Agreement shall inure to the benefit of and be binding upon the parties and their successors, trustees, permitted assigns or receivers.

22.3         The parties agree to perform all acts and things and to execute and deliver all documents necessary or appropriate to give effect to the intent and purpose of this Agreement.

22.4        any portion of the payment in 2.13.1may also be satisfied by Licensee’s assumption of a corresponding dollar amount of BONU debt.

22.4        Any waiver by either party of any rights arising from any breach of the terms of this Agreement shall not be construed as a continuing waiver of other breaches of the same or other terms of this Agreement by the other party.

22.5         Nothing in this Agreement shall create a partnership or agency or joint venture between the parties.

 

  

17

  

 

22.6         Each party agrees with the other to be just and faithful in all its activities and dealings with the other party, and in the performance of its obligations, express and implied, under this Agreement.

Signature /s/ Andrew Kielbania 

Name   Andrew Kielbania

Signature  /s/ Wayne Johnson

Name   Wayne Johnson

Signed for and on behalf of                                  by its duly authorized Representative 

(i)

(ii)

Position Signed for and on behalf of                  by its duly authorized Representative

Position

 

  

18

  

 

PATENTS

FIRST SCHEDULE

A non-provisional application for patent for “Compositions for treating and removing -noxious materials malodors and microbes, and -methods of use and -preparation thereof” (Docket No.: JG- HPAC-5186; filed March 30, 2005 in the U.S. Patent and Trademark Office).

All patent applications to date

AGREEMENT TO LICENSE INVENTION

SECOND SCHEDULE

TRADE MARKS USA:

MARKS:

BIONEUTRAL

OGIENE

YGIENE

Auto Neutral

GOODS:

Antimicrobial chemical preparation for use as a bactericide, sporicide, fungicide, or virucide.

Chemical preparation used in the prevention and elimination of noxious odors and/or dangerous chemicals which form as a result of the decomposition of human or industrial waste or in the manufacturing process or the burning of any material including fossil fuel, or in connection with human or pet odor or the improvement of human or animal condition.

House mark for a full line of chemical preparations for the prevention and elimination of harmful microbes including bacteria, viruses, yeast and mold fungi, toxic gases that are responsible for poor air quality and noxious gases that create unhealthy odors.

Chemical preparation for use in the prevention and elimination of toxic and noxious gases, as well as the attendant unhealthy odors, present in the air and on surfaces.

Chemical preparation for use in the prevention and elimination of toxic and noxious gases, as well as the attendant unhealthy odors, present in the air and on surfaces.

Mark

Class

Application No.

File Ref

Status

BIOMEDEX (word mark)

1

679490

28833

Granted - Renewal due 23/05/2010

5

679491

28834

Granted - Renewal due 23/05/2010

10

679492

28835

Granted - Renewal due 23/05/2010

37

679493

28836

Granted - Renewal due 23/05/2010

 

  

19

  

 

AGREEMENT TO LICENSE INVENTION

EXHIBIT A (FOR SALES & DISTRIBUTION)

Pursuant to a certain Agreement to Licence Invention (the “License Agreement”) dated as of ________________ between BONU and Licensee”), Licensee was granted the exclusive right to distribute, promote, use and sell Licensed Products in the Territory (as defined in the License Agreement), subject to the provisions of the License Agreement). Among such provisions is the requirement that all contracts between Licensee and any third party relating to the distribution, promotion, use and sale of any Licensed Products contain the language stated herein.

 

Licensee now desires to enter into such a contract (the “Principal Agreement”) with __________________ (the “Third Party”) for the purpose of __________ (the “Contracted Task”). In consideration of Licensee entering into such contract with Third Party, Third Party hereby agrees as follows:

 

1.           The Third Party shall not sell, distribute or supply, or cause, allow or permit any wholesaler, distributor or other agent or representative of Third Party to sell, distribute or supply, any Licensed Products to another party (a) that is located outside the Territory other than to an Authorized Ex Territory Purchaser (as defined in the License Agreement) or (b) that is located inside the Territory if the Third Party suspects or believes, or has reasonable cause or grounds to suspect or believe, that any Licensed Products sold, distributed or supplied to such other party might either be (i) used by such other party outside the Territory (other than use of a consumer product by an end-user) or (ii) subsequently resold or distributed by such other party (or any agent or representative of such other party) outside the Territory. BONU and its successors and assigns shall be deemed to be a third party beneficiary under this paragraph, shall have the right to proceed directly against, and obtain damages and other remedies from, the Third Party in the event of any breach of the foregoing sentence. No amendment, waiver or other modification of either of the two immediately preceding sentences or this sentence shall be effective except to the extent expressly set forth in writing signed and delivered by BONU (or such successors and assigns, as applicable).

 

2.           If, but for this clause, any provision (or any part of any provision) of this Agreement would be unenforceable or invalid by reason of any statute or any rule of law or equity, the same shall be severed from this Agreement, with the intent that the remaining parts of this Agreement shall not be affected thereby but shall remain in full force and effect.

AGREEMENT TO LICENSE INVENTION

 

3.           This Agreement shall survive the termination or expiration of the Principal Agreement.

Executed this __ day of _______________, 20__

___________________________________________ By:___________________________________

 

 

  

20

  

 

_________

AGREEMENT TO LICENSE INVENTION

 

EXHIBIT B (FOR MANUFACTURING)

Pursuant to a certain Agreement to License Invention (the “License Agreement”) dated as of ________________ between BONU  and Licensee, Licensee was granted the exclusive right to manufacture, distribute, promote, use and sell Licensed Products in the Territory (as defined in the License Agreement), subject to the provisions of the License Agreement). Among such provisions is the requirement that all contracts between Licensee and any third party relating to the manufacture of any Licensed Products contain the language stated herein.

 

Licensee now desires to enter into such a contract (the “Principal Agreement”) with __________________ (the “Third Party”) for the purpose of __________ (the “Contracted Task”). In consideration of Licensee entering into such contract with Third Party, Third Party hereby agrees as follows:

 

1. NON-DISCLOSUREOFCONFIDENTIALINFORMATION

1.1.         Confidential Information as used in this Agreement means and encompasses: technical and other information concerning the development, research, testing, design and manufacture of the Licensed Products; trademarks; know-how and intellectual property; and any and all other information of BONU; commercial information relating to the business and business methods of BONU, including, but not limited to, trade secrets, new product initiatives, manufacturing methodologies, financial information, supplier lists, customer lists, details of client relationships, pricing structures, costs and profit margins, research plans, business plans, promotional and marketing plans; promotional and marketing material; promotional strategies, stock range and levels, sales records, planned improvements, past or present or planned research and development, regulatory compliance documents and applications, and employees’ details and records; and any information that is, by its nature, confidential or that BONU has advised Licensee in writing is confidential. Information shall be deemed Confidential Information whether it is delivered in written form, orally or visually or by demonstration or in some other manner, whether in permanently recorded form or not.

 

1.2.          The Confidential Information has been, or will be, provided to Third Party solely for the purpose of enabling Third Party to handle the Licensed Products and to perform the Contracted Task. The Third Party warrants that it will not make any use of the Confidential Information for any other purpose. The Third Party shall maintain in the strictest confidence and safeguard all Confidential Information and agrees that the Confidential Information shall not be disclosed to anyone except in accordance with this Agreement. Without limitation of the foregoing obligation and except as otherwise permitted by this Agreement, Third Party shall not, without the prior express written approval of licensee:

 

1.2.1       disclose, divulge, pass on or otherwise make available directly or indirectly all or part of the Confidential Information to any person or organization outside Third Party; or

 

1.2.2       use all or any part of the Confidential Information other than for the purpose of this Agreement or otherwise in any way that could reasonably be to be detrimental to or in conflict with the interests of BONU In the event that Third Party becomes legally compelled to disclose any of the Confidential Information to the courts of any competent jurisdiction, or to any government regulatory agency or financial authority, Third Party shall:

 

1.3.1       inform Licensee as soon as is reasonably practicable; and allow Licensee and/or BONU a reasonable time to oppose or limit such disclosure or, at the request of Licensee and/or BONU, seek to persuade the court, agency or authority to have the information treated in a confidential manner (where this is possible under the court, agency or authority’s procedures).

 

  

21

  

 

AGREEMENT TO LICENSE INVENTION

In the event that a protective order or other remedy is not obtained, Third Party shall furnish only that portion of the Confidential Information which is legally required to be furnished.

 

1.4.          Third Party shall take all necessary actions to maintain the security of the Confidential Information, including:

 

1.4.1       securely storing the Confidential Information and restricting and controlling access to it; refraining from taking all or any part of the Confidential Information in tangible form onto the premises of any third party without the prior express written consent of licensee; and

 

1.4.2        protecting electronically stored Confidential Information using secret passwords or some other encryption method approved in writing by licensee.

 

1.5.           In addition, the Third Party shall restrict access to such information to those of its employees, directors and advisors with a need to know such information in order to perform Contracted Task. Such employees shall, by written agreement with Third Party, acknowledge their obligation to protect such information of licensee and, upon request, Third Party will furnish such employee agreements to Licensee and/or BONU. Third Party will take all necessary steps to prevent its employees, directors and advisors from disclosing, all or any part of the Confidential Information to any unauthorized person or third party.

1.6.          The Third Party shall on request from Licensee  return to Licensee  all Confidential Information provided to Third Party in written, printed or tangible form together with all copies taken thereof. The Third Party shall upon request of Licensee  permanently and securely delete all Confidential Information that resides on any computers or databases maintained by Third Party.

 

1.7.          Third Party shall promptly notify Licensee if it becomes aware of (a) any breach of confidence by any person, firm or corporation or (b) any person, firm or corporation who has become aware of any Confidential Information in an unauthorized way. Third Party shall give Licensee  and/ or BONU all reasonable assistance with any lawsuits or other legal actions, for breach of confidence or otherwise, by Licensee and/or BONU against such person, firm or corporation including, but not limited to, actions for extraordinary relief by Licensee and/or BUSA against such person, firm or corporation.

 

1.8.           Third Party will, upon receipt of written notice from Licensee and/or BONU of a perceived breach of any term of this Agreement, refrain from disclosing or using (other than for the purpose of the Principal Agreement) the information identified in the notice for thirty (30) days from the date of the notice, to enable Licensee and/or BONU to seek urgent relief.

 

 

  

22

  

 

1.9.           In the event of any actual, presumed or threatened breach of confidence or loss of secrecy, Third Party will refrain from disclosing or using (other than for the purpose of this Agreement) that Confidential Information for a further period of thirty (30) days from the date of notice, to give Licensee and/or BONU an opportunity to seek urgent relief in the event that Licensee and/or BONU is of the opinion that the relevant Confidential Information is not in the public domain or remains subject to the terms of this Agreement.

 

1.10.        In the event Third Party is in any doubt whatsoever as to whether any information is Confidential Information, can be used for a particular purpose or can be disclosed to a particular third party, Third Party will treat that information as Confidential Information, refrain from using that information for that particular purpose or disclosing that information to that particular third party, unless licensee gives explicit written consent to do otherwise. In the case of any dispute as to whether any information is Confidential Information, the onus will be on Third Party to prove that such information is not Confidential Information.

 

1.11.       Third Party will fully and effectively indemnify Licensee and/or BONU against all losses, costs, damages, claims, liabilities and expenses (including, without limitation, reasonable attorneys' fees and other expenses of investigation, enforcement, defense and appeal) that Licensee and/or BONU may incur as a result of any unauthorized use or disclosure of all or any part of the Confidential Information by Third Party or any of its directors, employees, and/or advisors.

1.12.       The Third Party agrees not to attempt to circumvent this Agreement in any way. In particular, Third Party agrees that it shall not attempt to reverse engineer or otherwise test for or obtain or learn the formulation, ingredients or components of the Licensed Products.

 

1.13.       The Third Party agrees that an actual or threatened violation by Third Party of this Agreement would cause Licensee and/or BONU irreparable harm, and that in addition to any other right or remedy Licensee and/or BONU may have, Licensee and/or BONU shall be entitled to extraordinary relief in Court including, but not limited to, temporary restraining orders, temporary injunctions, permanent injunctions (all without the requirement that a bond or undertaking be posted) and exemplary damages in the event of any breach of this Agreement.

 

1.14.        Unless otherwise stated, nothing in this Agreement shall be construed to grant to Third Party any right or license under any patent, trademark, copyright or other intellectual property right of BONU or any other entity in respect of the Confidential Information.

 

2. GENERAL

 

2.1           If, but for this clause, any provision (or any part of any provision) of this Agreement would be unenforceable or invalid by reason of any statute or any rule of law or equity, the same shall be severed from this Agreement, with the intent that the remaining parts of this Agreement shall not be affected thereby but shall remain in full force and effect.

2.2 This Agreement shall survive the termination or expiration of the Principal Agreement.

Executed this __ day of _______________, 20__

___________________________________________ By:___________________________________

 

 

  

23

  

 

THIRD SCHEDULE

BONU TO INSERT ALL PATENTS AND IP DETAILS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}]]